Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 9/20 | 0.46 |
| ▸ | ESR1 | P03372 | 8/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 2/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | TLR2 | O60603 | 1/20 | 0.37 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.37 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL562872 | 0.82 | ALDH1A1 (0.41) | ESR2ESR1ALDH1A1TSHRKCNJ1 | |
| SCHEMBL13139867 | 0.81 | ALDH1A1 (0.42) | ALDH1A1TSHRKCNJ1ERN1TYR | |
| SCHEMBL19897782 | 0.80 | ALDH1A1 (0.52) | ALDH1A1TSHRKCNJ1ERN1MEN1 | |
| SCHEMBL30395616 | 0.80 | ALDH1A1 (0.52) | ALDH1A1TSHRKCNJ1ERN1MEN1 | |
| SCHEMBL8373514 | 0.79 | ESR2 (0.55) | ESR2ESR1HSD17B1ALDH1A1ANPEP | |
| SCHEMBL3932855 | 0.79 | ALDH1A1 (0.59) | ALDH1A1TSHRKCNJ1ERN1MEN1 | |
| SCHEMBL30340593 | 0.79 | ALDH1A1 (0.59) | ALDH1A1TSHRKCNJ1ERN1MEN1 | |
| SCHEMBL13140085 | 0.78 | ERN1 (0.46) | ESR2ESR1ALDH1A1TSHRKCNJ1 | |
| SCHEMBL25424114 | 0.78 | ERN1 (0.53) | ALDH1A1TSHRKCNJ1ERN1MEN1 | |
| SCHEMBL31051635 | 0.78 | ERN1 (0.53) | ALDH1A1TSHRKCNJ1ERN1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267775-A1 | OXADIAZOLIDINEDIONE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20100267775-A1 | OXADIAZOLIDINEDIONE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20100267775-A1 | OXADIAZOLIDINEDIONE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-21 | — | — | US | disclosed |
| EP-2216330-A1 | OXADIAZOLIDINEDIONE COMPOUND | Astellas Pharma Inc. (JP) | 2010-08-11 | — | — | EP | disclosed |
| EP-2216330-A1 | OXADIAZOLIDINEDIONE COMPOUND | Astellas Pharma Inc. (JP) | 2010-08-11 | — | — | EP | disclosed |
| US-7732626-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-08 | — | — | US | disclosed |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | GPR119, GLP1R, GPR65 | ESR2 612/4885ESR1 274/4885HSD17B1 282/4885 |
| US-20100267775-A1 | OXADIAZOLIDINEDIONE COMPOUND | GPR119, GLP1R, GPR4 | ESR2 1033/4885ESR1 299/4885HSD17B1 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.